strongly with sputum and blood eosinophil counts, and are most useful when a moving average is taken over approximately 9 days. Further studies are required to determine if daily FeNO measurements may have a role in predicting loss of asthma control or exacerbations.

P70 BLOOD EOSINOPHIL COUNTS IN NORMAL CONTROLS WITH NO HISTORY OF ALLERGIC DISEASE

¹A Anand, ¹O Ahmed, ¹ID Pavord, ²M McClure, ²B Ferry, ²SR Pavord. ¹University of Oxford, Oxford, UK; ²Oxford University Hospitals, Oxford, UK

10.1136/thoraxjnl-2015-207770.207

Background The beneficial effect of corticosteroids and anti-interleukin (IL)-5 on exacerbations of airway disease becomes apparent at blood eosinophil counts above $0.15 \times 10^9/L$, well within the normal range. One potential explanation is that the upper limit of the normal range is artificially high because studies have included patients with allergic disease and eosinophilic inflammation. We have assessed the normal range for blood eosinophil counts in volunteers with no self-reported history of allergic disease and compared this with the findings from a more traditional control population.

Methods We recruited 78 volunteers (15 male) with a mean age of 38.8 years. Volunteers with a self-reported history of asthma, allergic rhinitis and/or eczema were excluded. The differential cell count was carried out using sysmex XN analyser and serum IgE measured using automated enzyme immunoassay by Phadia Immucap equipment. Results were compared with an unscreened population ($n = 120$) used to calculate our local normal ranges.

Results One outlier value of $0.79 \times 10^9/L$, (>5 SD above the mean) was excluded from further analysis. In the remainder the mean blood eosinophil count was $0.15 \times 10^9/L$ with an upper limit of normal range of $0.27 \times 10^9/L$. Volunteers with no self-reported history of allergic disease but an IgE >120 iu/L and/or positive specific IgE to house dust mites or grass were not statistically different. The mean blood eosinophil count in the laboratory population was $0.19 \times 10^9/L$ (p 0.018 vs our population) and the upper limit of normal range $0.42 \times 10^9/L$.

Conclusions The upper limit of the normal range for blood eosinophil count is lower in a population who have no clinical history of allergic disease.

P71 THE RELATIONSHIP BETWEEN THE LEICESTER COUGH QUESTIONNAIRE, EOSINOPHILIC AIRWAY INFLAMMATION AND ASTHMA PATIENT RELATED OUTCOME MEASURES IN SEVERE ASTHMA

¹S Siddiqui, ¹R Free, ¹P Bradding, ²L McGarvey. ¹Leicester NIHR Respiratory Biomedical Research Unit, University of Leicester, Department of Infection, Immunity and Inflammation, Leicester, UK; ²Queen University Belfast, School of Medicine, Dentistry and Biomedical Sciences, Belfast, Ireland

10.1136/thoraxjnl-2015-207770.208

Background Severe asthma is characterised by a variety of symptoms which include chronic cough, although the mechanisms responsible are poorly understood. Modulation of cough reflex sensitivity by eosinophilic airway inflammation is considered likely but has not been well studied. Likewise the impact of chronic cough on patients health status is not well known as existing asthma patient related outcome instruments such as the

Juniper Asthma Control Score (ACQ-6), Asthma Quality of Life Questionnaire (AQLQ) were not primarily designed to capture cough and its related morbidity in asthma. We sought to evaluate (i) the Leicester Cough Questionnaire (LCQ) in a severe asthma population, (ii) the relationship between the Leicester Cough Questionnaire (LCQ) and the ACQ-6, AQLQ and (iii) airway inflammation in sputum in severe asthma patients.

Methods 312 patients [mean (SD) age of 60.4(16.2) years, median (IQR) GINA treatment score 5[4–5] and median (IQR) sputum eosinophil percentage of 3.0(0.5–16.6)] attending the Leicester difficult asthma service were evaluated with the LCQ, ACQ-6 and AQLQ at a single clinical visit. Induced sputum samples were also acquired at the same visit for differential cell count.

Results The LCQ demonstrated the following distribution properties: mean 15.30, standard deviation 4.49, range 4.04–21 and 10th percentile point of 8.52. Domain specific scores were LCQ (physical) 4.8(1.45), LCQ (psychological) 5.30 (1.55) and LCQ (social) 5.19(1.67). There were modest correlations between LCQ and ACQ-6 ($r = -0.60$; $p < 0.001$) but not with AQLQ ($r = -0.067$). There was no correlation between LCQ and sputum eosinophils/neutrophils.

Discussion Severe asthma is associated with a high degree of cough related morbidity that appears to be independent of eosinophilic airway inflammation and not captured fully by available patient reported outcome instruments. Further research is required to determine the validity of the LCQ and its responsiveness in severe asthma populations.

P72 T2 BIOMARKERS RELATE TO EXACERBATIONS AND CONTROL IN REFRACTORY ASTHMA

S Srivastava, A Sahal, A Mansur. Birmingham Heartlands Hospital, Birmingham, UK

10.1136/thoraxjnl-2015-207770.209

Background T2 biomarkers have been shown to predict responsiveness to corticosteroids and possibly relate to asthma exacerbations and control. T2 biomarkers in the form of fraction exhaled nitric oxide (FeNO), peripheral blood eosinophils (PBE), and serum periostin are easier to measure and probable surrogate markers for induced sputum eosinophilia (ISE). The relationships between PBE, FeNO and periostin particularly in refractory asthma have been conflicting. A composite score of T2 biomarkers has also been postulated to predict exacerbations and may be more sensitive.¹

Aim To explore the relationship between the T2 biomarkers individually, and in the form of composite score to asthma exacerbations and control.

Methods Unselected consecutive patients with confirmed diagnosis of refractory asthma (ATS) attending a tertiary severe asthma centre were recruited following an informed consent. Participants were evaluated for the followings: demographics, exacerbations requiring corticosteroids in the preceding 12 months, asthma control questionnaire (Juniper ACQ7), lung function, FeNO, PBE, and periostin measurement. The composite T2 score of all the 3 biomarkers was calculated as previously reported (reference). Statistical analyses were conducted using MedCalc software.

Results One-hundred and fifteen patients were recruited with mean age 45 yrs, 88 (69.8%) females, mean inhaled corticosteroids (BDP equivalent) = 1,647 μ g/day, on maintenance OCS =

63 (55%), mean FEV1 = 2.0 L (SD1.8–2.1), FEV1% pred = 68%, and mean FEV1/FVC ratio = 71% (SD = 68–74).

A significant positive correlation between FeNO and PBE was observed ($r = 0.39$, $p = 0.004$), but not with periostin. Only FeNO significantly correlated to exacerbations ($r = 0.42$, $p = 0.0008$) and only periostin correlated significantly to ACQ7 score ($r = 0.33$, $p = 0.0053$). In addition, the biomarkers composite score significantly correlated with exacerbations ($r = 0.4$, $p = 0.0031$) (Figure 1), but not ACQ7.

Abstract P72 Figure 1 The relationship between T2 composite score and annual OCS requiring exacerbations

Conclusion In real life settings, FeNO correlated with historical exacerbations and the T2 composite score displayed a dose response correlation with exacerbations frequency. Periostin correlated with ACQ7 but not exacerbations. Further research is required to confirm these findings.

REFERENCE

1 Heaney LG, et al. *Thorax* 2015;0:1–3. doi:10.1136/thoraxjnl-2015-207326

P73 A PILOT STUDY TO INVESTIGATE THE USE OF SERUM INHALED CORTICOSTEROID CONCENTRATION AS A POTENTIAL MARKER OF TREATMENT ADHERENCE IN SEVERE ASTHMA

¹KE George, ²BG Keevil, ³G Tavernier, ³K Hince, ³DM Ryan, ¹SJ Fowler, ³RM Niven. ¹University of Manchester and National Institute of Health Research Respiratory and Allergy Clinical Research Facility, University Hospital of South Manchester, Manchester, UK; ²Biochemistry Department, University Hospital of South Manchester, Manchester Academic Health Science Centre, Manchester, UK; ³Severe Asthma Clinic, North West Lung Centre, University Hospital South Manchester, Manchester, UK

10.1136/thoraxjnl-2015-207770.210

Background Inhaled anti-inflammatory therapy is fundamental to asthma management, but adherence is very poor. This increases the risk of exacerbations and poor symptom control. Currently there is no direct way of assessing adherence to inhaled steroids accurately. The primary aim of this project was to determine whether liquid chromatography tandem mass spectrometry could be used to detect fluticasone propionate (FP) in human serum as a potential aid to therapeutic monitoring. The secondary aim was to relate serum levels of FP to markers of asthma severity.

Methods We collected blood samples over an 8 hr period from inpatients with severe asthma on a stable dose of inhaled FP. Following baseline (trough) sampling, patients were observed using their inhaler, with inhaler technique documented. Subsequent samples were obtained 1, 2s, 4 and 8 hrs post inhalation. Demographic details and spirometry were also recorded.

Results Thirteen patients were recruited: 8 males, 5 females; age range 22–64 yrs; FEV1 range 53–101% predicted; 10 patients on 1000 mcg/day, and three on 2000 mcg/day FP. The mean concentration of FP at 1 hr post inhaler (peak in 7/13 patients) was 95.5 (SD 89.1) ng/L. The mean pre-dose trough concentration was 32.9 (SD 41.5) ng/L. Two patients were noted to have poor inhaler technique; these patients had some of the lowest serum FP levels recorded. The FEV1% predicted was found to be strongly correlated with the peak serum FP concentration (Pearson's $r = 0.8$, $p = 0.001$).

Conclusion We have demonstrated that FP can be detected in the blood of patients with severe asthma following directly observed therapy; this could have a potential future application as a direct measure of adherence and perhaps inhaler technique. We also demonstrated a profound effect of reduced lung function predicting low serum FP levels. Future work will explore whether poor absorption reflects relatively poor efficacy in the most severe patients.

Abstract P73 Figure 1 Serum concentration of FP at sampling timepoints; dashed lines represent individual patients; solid line group mean

P74 PREVALENCE OF SPECIFIC ANTIBODY DEFICIENCY IN SEVERE ASTHMA

¹S Zaidi, ¹G Tavernier, ¹D Ryan, ¹RM Niven, ²SJ Fowler. ¹University of Manchester, National Institute of Health Research, Respiratory and Allergy Clinical Research Facility, University Hospital South Manchester, Manchester, UK; ²Institute of Inflammation and Repair, Manchester Academic Health Sciences Centre, University of Manchester, National Institute of Health Research Respiratory and Allergy Clinical Research Facility, University Hospital South Manchester, Manchester, UK

10.1136/thoraxjnl-2015-207770.211

Introduction Patients with asthma are prone to recurrent infective exacerbations, due to viral or bacterial infections. We have previously presented retrospective data, demonstrating